S&P 500   4,994.03 (+0.54%)
DOW   38,162.19 (+0.46%)
QQQ   416.11 (+0.35%)
AAPL   165.60 (+0.36%)
MSFT   398.82 (-0.08%)
META   479.69 (-0.29%)
GOOGL   156.18 (+1.36%)
AMZN   175.48 (+0.49%)
TSLA   141.76 (-3.60%)
NVDA   785.19 (+3.04%)
AMD   146.98 (+0.23%)
NIO   3.94 (+3.68%)
BABA   70.20 (+1.64%)
T   16.19 (-1.94%)
F   12.86 (+5.93%)
MU   108.07 (+1.22%)
GE   150.15 (+1.41%)
CGC   7.90 (-0.38%)
DIS   112.25 (-0.32%)
AMC   3.35 (+6.01%)
PFE   26.30 (+1.15%)
PYPL   62.79 (+0.77%)
XOM   120.69 (+0.68%)
S&P 500   4,994.03 (+0.54%)
DOW   38,162.19 (+0.46%)
QQQ   416.11 (+0.35%)
AAPL   165.60 (+0.36%)
MSFT   398.82 (-0.08%)
META   479.69 (-0.29%)
GOOGL   156.18 (+1.36%)
AMZN   175.48 (+0.49%)
TSLA   141.76 (-3.60%)
NVDA   785.19 (+3.04%)
AMD   146.98 (+0.23%)
NIO   3.94 (+3.68%)
BABA   70.20 (+1.64%)
T   16.19 (-1.94%)
F   12.86 (+5.93%)
MU   108.07 (+1.22%)
GE   150.15 (+1.41%)
CGC   7.90 (-0.38%)
DIS   112.25 (-0.32%)
AMC   3.35 (+6.01%)
PFE   26.30 (+1.15%)
PYPL   62.79 (+0.77%)
XOM   120.69 (+0.68%)
S&P 500   4,994.03 (+0.54%)
DOW   38,162.19 (+0.46%)
QQQ   416.11 (+0.35%)
AAPL   165.60 (+0.36%)
MSFT   398.82 (-0.08%)
META   479.69 (-0.29%)
GOOGL   156.18 (+1.36%)
AMZN   175.48 (+0.49%)
TSLA   141.76 (-3.60%)
NVDA   785.19 (+3.04%)
AMD   146.98 (+0.23%)
NIO   3.94 (+3.68%)
BABA   70.20 (+1.64%)
T   16.19 (-1.94%)
F   12.86 (+5.93%)
MU   108.07 (+1.22%)
GE   150.15 (+1.41%)
CGC   7.90 (-0.38%)
DIS   112.25 (-0.32%)
AMC   3.35 (+6.01%)
PFE   26.30 (+1.15%)
PYPL   62.79 (+0.77%)
XOM   120.69 (+0.68%)
S&P 500   4,994.03 (+0.54%)
DOW   38,162.19 (+0.46%)
QQQ   416.11 (+0.35%)
AAPL   165.60 (+0.36%)
MSFT   398.82 (-0.08%)
META   479.69 (-0.29%)
GOOGL   156.18 (+1.36%)
AMZN   175.48 (+0.49%)
TSLA   141.76 (-3.60%)
NVDA   785.19 (+3.04%)
AMD   146.98 (+0.23%)
NIO   3.94 (+3.68%)
BABA   70.20 (+1.64%)
T   16.19 (-1.94%)
F   12.86 (+5.93%)
MU   108.07 (+1.22%)
GE   150.15 (+1.41%)
CGC   7.90 (-0.38%)
DIS   112.25 (-0.32%)
AMC   3.35 (+6.01%)
PFE   26.30 (+1.15%)
PYPL   62.79 (+0.77%)
XOM   120.69 (+0.68%)
NASDAQ:LUMO

Lumos Pharma (LUMO) Stock Price, News & Analysis

$2.61
+0.02 (+0.77%)
(As of 11:38 AM ET)
Today's Range
$2.60
$2.67
50-Day Range
$2.45
$3.15
52-Week Range
$2.41
$4.55
Volume
2,586 shs
Average Volume
20,488 shs
Market Capitalization
$21.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00

Lumos Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
595.0% Upside
$18.00 Price Target
Short Interest
Bearish
5.94% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Lumos Pharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$7,460 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.80) to ($2.00) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.67 out of 5 stars

Medical Sector

634th out of 907 stocks

Pharmaceutical Preparations Industry

286th out of 428 stocks

LUMO stock logo

About Lumos Pharma Stock (NASDAQ:LUMO)

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its primary product candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 3 clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.

LUMO Stock Price History

LUMO Stock News Headlines

Contrasting Ainos (NASDAQ:AIMD) and Lumos Pharma (NASDAQ:LUMO)
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Q4 2023 Lumos Pharma Inc Earnings Call
Lumos Pharma: Q4 Earnings Insights
Earnings Preview: Lumos Pharma
Lumos Pharma FY 2023 Earnings Preview
See More Headlines
Receive LUMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lumos Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
4/22/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LUMO
Employees
33
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.00
High Stock Price Target
$28.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+589.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-34,030,000.00
Net Margins
-1,659.39%
Pretax Margin
-1,660.80%

Debt

Sales & Book Value

Annual Sales
$2.05 million
Book Value
$3.45 per share

Miscellaneous

Free Float
6,055,000
Market Cap
$21.18 million
Optionable
Not Optionable
Beta
0.65
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Richard J. Hawkins (Age 75)
    Founder, CEO & Chairman
    Comp: $975.72k
  • Dr. John C. McKew Ph.D. (Age 60)
    Chief Scientific Officer & President
    Comp: $943.46k
  • Ms. Lori D. Lawley CPA (Age 40)
    CFO & Principal Accounting Officer
    Comp: $596.57k
  • Lisa Miller
    Senior Director of Investor Relations
  • Mr. Bradley J. Powers J.D. (Age 45)
    Chief Compliance Officer & General Counsel
    Comp: $677.08k
  • Mr. Aaron Schuchart B.B.A. (Age 58)
    CPA, M.B.A., Chief Business Officer
  • Dr. Pisit Pitukcheewanont FAAP
    M.D., Chief Medical Officer
  • Mr. Eddie L. Varnado M.B.A.
    Corporate Controller

LUMO Stock Analysis - Frequently Asked Questions

Should I buy or sell Lumos Pharma stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lumos Pharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LUMO shares.
View LUMO analyst ratings
or view top-rated stocks.

What is Lumos Pharma's stock price target for 2024?

3 equities research analysts have issued 1 year target prices for Lumos Pharma's shares. Their LUMO share price targets range from $10.00 to $28.00. On average, they expect the company's stock price to reach $18.00 in the next year. This suggests a possible upside of 595.0% from the stock's current price.
View analysts price targets for LUMO
or view top-rated stocks among Wall Street analysts.

How have LUMO shares performed in 2024?

Lumos Pharma's stock was trading at $3.18 at the start of the year. Since then, LUMO shares have decreased by 18.6% and is now trading at $2.59.
View the best growth stocks for 2024 here
.

When is Lumos Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our LUMO earnings forecast
.

How were Lumos Pharma's earnings last quarter?

Lumos Pharma, Inc. (NASDAQ:LUMO) issued its quarterly earnings results on Thursday, March, 7th. The company reported ($1.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.18) by $0.01. The firm earned $0.83 million during the quarter, compared to the consensus estimate of $0.01 million. Lumos Pharma had a negative net margin of 1,659.39% and a negative trailing twelve-month return on equity of 85.63%. During the same quarter last year, the business earned ($0.98) earnings per share.

What other stocks do shareholders of Lumos Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lumos Pharma investors own include Advanced Micro Devices (AMD), Agilent Technologies (A), Air Lease (AL), Bionano Genomics (BNGO), Chimerix (CMRX), Compagnie de Saint-Gobain (CODYY) and

How do I buy shares of Lumos Pharma?

Shares of LUMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LUMO) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners